Tirzepatide & Semaglutide: Heart Protection Breakthrough
- New research published in Nature Medicine and presented at the American Heart Association Scientific Sessions 2025 demonstrates that both tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) considerably reduce...
- Published November 14, 2024, the study analyzed data from nearly one million adults, offering crucial insights into the cardiovascular benefits of these increasingly popular medications.
- Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for weight loss, has already established its cardiovascular benefits.
“`html
Tirzepatide and Semaglutide Show Comparable Heart Protection in large Real-World Study
Table of Contents
New research published in Nature Medicine and presented at the American Heart Association Scientific Sessions 2025 demonstrates that both tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) considerably reduce the risk of major cardiovascular events in patients wiht type 2 diabetes.
Published November 14, 2024, the study analyzed data from nearly one million adults, offering crucial insights into the cardiovascular benefits of these increasingly popular medications.
Background: the rise of GLP-1 and GIP receptor Agonists
Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for weight loss, has already established its cardiovascular benefits. The SELECT trial, published in The New England Journal of Medicine on August 8, 2023, showed a 20% reduction in the risk of cardiovascular events in overweight or obese adults with established cardiovascular disease (“Cardiovascular Outcomes in Overweight or obese Adults with Semaglutide”).
Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated extraordinary efficacy in lowering blood sugar and promoting weight loss. Though, until now, direct evidence of its cardiovascular protection in a real-world setting was lacking. The SURPASS trials established its glucose-lowering and weight-loss capabilities, but large-scale cardiovascular outcome data was needed (“Tirzepatide Once weekly for the Treatment of Type 2 Diabetes”).
Study Design: A Real-World Data Approach
Researchers at Mass General Brigham, led by Dr. Nils Krüger, analyzed data from a national health insurance database, encompassing nearly one million adults diagnosed with type 2 diabetes between January 1, 2018, and December 31, 2022. The study focused on individuals who initiated treatment with tirzepatide, semaglutide, or sitagliptin (a commonly used DPP-4 inhibitor).
“Randomized controlled trials are frequently enough considered the reference standard in the medical evidence generation process. Though, not all questions can be answered using this time- and resource-intensive method,” explained Dr. Krüger. “Data generated in clinical practice and used secondarily for research allow us to address a wide range of clinically relevant questions time- and resource-effectively — when applied correctly. Moreover, we can study patients who reflect the reality of everyday clinical care, in contrast to the highly selected participants of randomized experiments.”
The primary outcome measured was a composite of major adverse cardiovascular events (MACE),including heart attack,stroke,and cardiovascular death. Researchers adjusted for a wide range of factors that could influence cardiovascular risk, such as age, sex, race, pre-existing conditions, and other medications.
key Findings: Comparable Risk Reductions
The analysis revealed that both